EA200401369A1 - SLOWLY RELAXING MEDICINAL COMPOSITIONS OF GUIPHENESINE - Google Patents

SLOWLY RELAXING MEDICINAL COMPOSITIONS OF GUIPHENESINE

Info

Publication number
EA200401369A1
EA200401369A1 EA200401369A EA200401369A EA200401369A1 EA 200401369 A1 EA200401369 A1 EA 200401369A1 EA 200401369 A EA200401369 A EA 200401369A EA 200401369 A EA200401369 A EA 200401369A EA 200401369 A1 EA200401369 A1 EA 200401369A1
Authority
EA
Eurasian Patent Office
Prior art keywords
guaifenesin
composition
modified release
releasing
dosing
Prior art date
Application number
EA200401369A
Other languages
Russian (ru)
Other versions
EA007156B1 (en
Inventor
Роберт Д. Дэвис
Рольф В. Блюм
Доналд Джеффри Кейсер
Original Assignee
Адамс Лэборетриз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/121,706 external-priority patent/US6955821B2/en
Priority claimed from US10/406,574 external-priority patent/US7985420B2/en
Priority claimed from US10/406,557 external-priority patent/US7838032B2/en
Application filed by Адамс Лэборетриз, Инк. filed Critical Адамс Лэборетриз, Инк.
Publication of EA200401369A1 publication Critical patent/EA200401369A1/en
Publication of EA007156B1 publication Critical patent/EA007156B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение касается новой фармацевтической композиции с модифицированным высвобождением гвайфенезина и, произвольно, второго лекарственного препарата, который предпочтительно отобран из декстрометорфана и псевдоэфедрина. Композиция может включать гидрофильный полимер, предпочтительно гидроксипропилметилцеллюлозу, и нерастворимый в воде полимер, предпочтительно акриловую смолу, в соотношении в пределах приблизительно 1:1 (один к одному) - 9:1 (девять к одному), более предпочтительно в пределах приблизительно 3:2 (три к двум) - 6:1 (шесть к одному) и наиболее предпочтительно в пределах приблизительно 2:1 (два к одному) - 4:1 (четыре к одному), по весу. Эта композиция способна обеспечивать терапевтически эффективное бионакопление гвайфенезина в организме человека по меньшей мере в течение двенадцати часов после дозировки. Изобретение также касается модифицировано высвобождающего продукта, который состоит из двух частей: одна часть включает немедленно высвобождающую композицию гвайфенезина, а другая часть - замедленно высвобождающую композицию гвайфенезина, где одна или обе части дополнительно включают декстрометорфан. Модифицировано высвобождающий продукт обеспечивает максимальную плазменную концентрацию гвайфенезина, которая эквивалентна концентрации, созданной немедленно высвобождающей таблеткой гвайфенезина, и способна к обеспечению терапевтически эффективного бионакопления гвайфенезина в организме человека в течение по крайней мере двенадцати часов после дозировки.Международная заявка была опубликована вместе с отчетом о международном поиске.The invention relates to a new pharmaceutical composition with modified release of guaifenesin and, optionally, a second drug, which is preferably selected from dextromethorphan and pseudoephedrine. The composition may comprise a hydrophilic polymer, preferably hydroxypropylmethylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio of about 1: 1 (one to one) to 9: 1 (nine to one), more preferably of about 3: 2 (three to two) - 6: 1 (six to one) and most preferably in the range of about 2: 1 (two to one) - 4: 1 (four to one), by weight. This composition is capable of providing therapeutically effective bioavailability of guaifenesin in the human body for at least twelve hours after dosing. The invention also relates to a modified release product, which consists of two parts: one part includes the immediately releasing guaifenesin composition and the other part the slow-releasing guaifenesine composition, where one or both parts additionally include dextromethorphan. The modified release product provides the maximum plasma concentration of guaifenesin, which is equivalent to the concentration created by the immediately releasing guaifenesin tablet, and is capable of providing a therapeutically effective bioaccumulation of guaifenesin in the human body for at least twelve hours after dosing. .

EA200401369A 2002-04-15 2003-04-15 Sustained release of guaifenesin combination drugs EA007156B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/121,706 US6955821B2 (en) 2000-04-28 2002-04-15 Sustained release formulations of guaifenesin and additional drug ingredients
US10/406,574 US7985420B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin combination drugs
US10/406,557 US7838032B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin
PCT/US2003/011500 WO2003088952A1 (en) 2002-04-15 2003-04-15 Sustained release of guaifenesin combination drugs

Publications (2)

Publication Number Publication Date
EA200401369A1 true EA200401369A1 (en) 2005-06-30
EA007156B1 EA007156B1 (en) 2006-08-25

Family

ID=29255202

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401369A EA007156B1 (en) 2002-04-15 2003-04-15 Sustained release of guaifenesin combination drugs

Country Status (10)

Country Link
EP (1) EP1503739A4 (en)
JP (1) JP5466346B2 (en)
CN (1) CN1655766B (en)
AU (1) AU2003237807B2 (en)
CA (1) CA2481739C (en)
EA (1) EA007156B1 (en)
IL (1) IL164438A0 (en)
MX (1) MXPA04010225A (en)
WO (1) WO2003088952A1 (en)
ZA (1) ZA200409171B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580652C2 (en) * 2009-02-04 2016-04-10 Астеллас Фарма Инк. Pharmaceutical composition for oral administration

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
BRPI0414719A (en) * 2003-09-24 2006-11-21 Combinatorx Inc therapeutic regimens for administering drug combinations
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
BRPI0513846A (en) * 2004-08-13 2008-05-20 Boehringer Ingelheim Int prolonged-release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method of manufacture thereof and use thereof
CN103214483B (en) 2005-12-13 2014-12-17 因塞特公司 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
CN1994285B (en) * 2006-01-04 2011-03-16 上海医药工业研究院 Sustained release micro-pellet of guaifenesin and preparation process thereof
WO2008089260A2 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
CN101658507B (en) * 2008-08-26 2011-12-07 北京科信必成医药科技发展有限公司 Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation
KR102283091B1 (en) 2010-03-10 2021-07-30 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9339478B2 (en) 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
CN103797010B (en) 2011-06-20 2016-02-24 因塞特控股公司 As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives
CN102755304A (en) * 2012-08-03 2012-10-31 四川百利药业有限责任公司 Preparation method of guaifenesin and dextromethorphan hydrobromide capsules
CR20190073A (en) 2012-11-15 2019-04-25 Incyte Holdings Corp DOSAGE FORMS OF RUXOLITINIB OF SUSTAINED RELEASE (Divisional 2015-265)
EP3030227B1 (en) 2013-08-07 2020-04-08 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
CN105982860B (en) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 Guaifenesin water-free swallowable taste-masking granule
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
CA2354057C (en) * 1998-12-11 2009-02-10 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
CN100391438C (en) * 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 Process for making aqueous coated beadlets
US6372525B1 (en) * 1999-12-20 2002-04-16 Taiwan Semiconductor Manufacturing Company Wafer-level antenna effect detection pattern for VLSI
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580652C2 (en) * 2009-02-04 2016-04-10 Астеллас Фарма Инк. Pharmaceutical composition for oral administration

Also Published As

Publication number Publication date
MXPA04010225A (en) 2005-07-05
IL164438A0 (en) 2005-12-18
EP1503739A1 (en) 2005-02-09
CN1655766A (en) 2005-08-17
CA2481739C (en) 2012-10-02
EA007156B1 (en) 2006-08-25
AU2003237807B2 (en) 2008-10-23
ZA200409171B (en) 2005-07-27
WO2003088952A1 (en) 2003-10-30
AU2003237807A1 (en) 2003-11-03
CN1655766B (en) 2012-05-30
EP1503739A4 (en) 2006-06-21
JP5466346B2 (en) 2014-04-09
JP2005528402A (en) 2005-09-22
CA2481739A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
EA200401369A1 (en) SLOWLY RELAXING MEDICINAL COMPOSITIONS OF GUIPHENESINE
Bouteille et al. Treatment perspectives for human African trypanosomiasis
Davis et al. Artemisinin‐based combination therapies for uncomplicated malaria
TW200727919A (en) Guaifenesin sustained release formulation and tablets
BR9405798A (en) Methods for in vivo release of biological material and useful compositions thereof
BRPI0408999A (en) compressed prolonged oral release multiparticulate tablets
ATE235895T1 (en) DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE
CA2309328A1 (en) Cyclic amine derivatives and their use as drugs
AR023972A1 (en) COMPOSITIONS OF MEDICINES BASED ON ANTI-POLINERGICALLY ACTIVE AND BETA-MIMETIC COMPOUNDS
AR023939A1 (en) COMPUTERS DERIVED FROM PIPERIDINE USEFUL AS AN ANTHOGONIST OF CCR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THE USE OF THE SAME ONLY OR IN COMBINATION WITH ANOTHER ANTIVIRAL AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT AND A KIT
De Clercq et al. Efficacy of artesunate and praziquantel in Schistosomahaematobium infected schoolchildren
EA200700049A1 (en) PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
HUP0302857A2 (en) Pharmaceutical formulation
IT1245890B (en) PHARMACEUTICAL FORMULATIONS FOR ORAL USE GASTRORESANTS CONTAINING BILE ACIDS.
BR0209658A (en) 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives
BR0313197A (en) Cytotoxic agents containing potent taxanes and their therapeutic use
JP2008526953A (en) Treatment of inflammatory diseases with Praziquantel
TW200503775A (en) Pharmaceutical composition and method for treating
EP1830191A3 (en) Pharmaceutical preparations containing thiazolidinediones for the treatment of endocrine autoimmune diseases
BR0314797A (en) Pyrimidineamide derivatives and their use
MA33463B1 (en) FIXED SOLID PHARMACEUTICAL DOSE COMPOSITIONS COMPRISING IRBESARTAN AND AMLODIPINE, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF
Meyer et al. Rewarding effects of the optical isomers of 3, 4-methylenedioxy-methylamphetamine (‘Ecstasy’) and 3, 4-methylenedioxy-ethylamphetamine (‘Eve’) measured by conditioned place preference in rats
CN102143687A (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
AR034813A1 (en) PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU